COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
Scientific title
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Campylobacter Jejuni Infection 0 0
Condition category
Condition code

Study type
Description of intervention(s) / exposure
Other interventions - LMN-101

Active Comparator: Part B: Cohort 1 - 300 mg PO TID given as a single 300-mg capsule of LMN-101 orally three times daily for 28 days

Active Comparator: Part B: Cohort 2 - 1000 mg PO TID given as two 500-mg capsules of LMN-101 orally three times daily for 28 days

Active Comparator: Part B: Cohort 3 - 3000 mg PO TID given as six 500-mg capsules of LMN-101 orally three times daily for 28 days

Other: Part A - 3000 mg PO single dose given as six 500-mg capsules of LMN-101 orally

Other interventions: LMN-101
variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Rates of adverse events in LMN-101 subjects compared to placebo subjects - adverse events graded according to severity and rates compared between LMN-101 subjects and placebo subjects
Timepoint [1] 0 0
Day 1 to Day 56
Primary outcome [2] 0 0
Tolerability of LMN-101: proportion of subjects completing study drug compared to placebo - proportion of subjects completing study drug and remaining on study and free from possibly drug-related and dose-limiting serious adverse events
Timepoint [2] 0 0
Day 1 to Day 56
Secondary outcome [1] 0 0
Pharmacokinetics: Peak serum concentration in LMN -101 subjects - Peak serum drug concentration in subjects receiving LMN-101
Timepoint [1] 0 0
Day 1 to Day 29
Secondary outcome [2] 0 0
Pharmacokinetics: area under the curve in serum - Area under the serum drug concentration versus time curve in subjects receiving LMN-101 at each dose level
Timepoint [2] 0 0
Day 1 to Day 29
Secondary outcome [3] 0 0
Anti-Drug Antibodies - Induction of serum anti-drug IgG antibodies
Timepoint [3] 0 0
Day 1 to Day 56

Key inclusion criteria
1. Male or female between 18 and 50 years, inclusive, at time of informed consent

2. Willingness to participate after written informed consent obtained

3. Available for all planned clinical visits for physical examinations, blood draws,
stool collections

4. General good health, without significant medical illness or abnormal physical
examination findings as determined by the PI.

5. Adequate bone marrow reserve, renal and liver function.

1. Absolute neutrophil count = 1.5 x 10e9/L

2. Lymphocyte count < 6.0 x 10e9/L

3. Platelet count = 150 x 10e9/L

4. Hemoglobin = 110 g/L

5. Estimated glomerular filtration rate = 40 mL/min/1.73 meter squared

6. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) = 3x upper
limit of normal (ULN)

7. Total bilirubin = 1.5x ULN

8. Serum albumin = 28 g/L

6. Females of childbearing potential should be using and committed to continue using one
of the following acceptable birth control methods:

1. Sexual abstinence (inactivity) or exclusively same-sex partner for 1 month prior
to screening through study completion; or

2. Intrauterine device (IUD) in place for at least 1 month prior to study through
study completion; or

3. Stable hormonal contraception for at least 1 month prior to study through study
completion; or

4. Surgical sterilization (vasectomy) of male partner at least 6 months prior to

7. To be considered of non-childbearing potential, females should be surgically
sterilized (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least
2 months prior to study) or be post-menopausal and at least 3 years since last menses.

8. Male participants must use condoms during the study and through study completion.
Minimum age
18 Years
Maximum age
50 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Treatment with an experimental compound within 30 days.

2. Treatment within 30 days or planned use within the study period with immunomodulator
or immunosuppressant agent.

3. Pregnancy or breastfeeding.

4. Presence of any of the following clinical conditions:

1. History of one or more of the following: cardiac insufficiency (NYHA III/IV),
uncontrolled cardiac arrhythmias, unstable ischemic heart disease, or
uncontrolled hypertension (systolic blood pressure > 170 mmHg or diastolic blood
pressure > 110 mmHg).

2. History of venous thromboembolic disease within 12 months, myocardial infarction,
or cerebrovascular accident.

3. Unstable pulmonary, renal, hepatic, endocrine or hematologic disease.

4. Gastrointestinal disorder requiring ongoing care by a physician.

5. Autoimmune disease, mixed connective tissue disease, scleroderma, polymyositis,
or significant systemic involvement secondary to rheumatoid arthritis.

6. Evidence of active malignant disease, malignancies diagnosed within the previous
5 years, or breast cancer diagnosed within the previous 5 years (except skin
cancers other than melanoma).

7. Known active current or history of recurrent bacterial, viral, fungal,
mycobacterial or other opportunistic infections; or major episode of infection
requiring hospitalization or treatment with IV antibiotics within 4 weeks.

8. Positive serology for human immunodeficiency virus (HIV) infection or history of
other immunodeficiency illness.

9. Positive serology results for hepatitis B surface antigen (HBsAg) or hepatitis C
virus (HCV)

10. Significant neuromuscular disease or neuropathy

11. Psychiatric condition

12. Alcohol or illicit drug abuse/dependency or positive urine toxicology screen for
drugs of abuse other than marijuana. Alcohol and tobacco consumption are

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Brisbane & Women's Hospital - Herston
Recruitment postcode(s) [1] 0 0
4029 - Herston

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Lumen Bioscience, Inc.

Ethics approval
Ethics application status

Brief summary
This will be a randomized, double-blind, placebo-controlled, dose-escalation study of 3 dose
levels of LMN-101. Healthy volunteers will take LMN-101 or placebo orally either as a single
dose or at one of three dose levels three times daily over 28 days. Protocol-specified
evaluations and procedures will be performed on Days 1-2 and every one-two weeks during
dosing. Study observation will continue until 4 weeks after the last dose of study drug.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Paul Griffin, MBBS
Address 0 0
Nucleus Network
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications